Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation Journal Article
| Authors: | Uy, G. L.; Costa, L. J.; Hari, P. N.; Zhang, M. J.; Huang, J. X.; Anderson, K. C.; Bredeson, C. N.; Callander, N. S.; Cornell, R. F.; Perez, M. A. D.; Dispenzieri, A.; Freytes, C. O.; Gale, R. P.; Garfall, A.; Gertz, M. A.; Gibson, J.; Hamadani, M.; Lazarus, H. M.; Kalaycio, M. E.; Kamble, R. T.; Kharfan-Dabaja, M. A.; Krishnan, A. Y.; Kumar, S. K.; Kyle, R. A.; Landau, H. J.; Lee, C. H.; Maiolino, A.; Marks, D. I.; Mark, T. M.; Munker, R.; Nishihori, T.; Olsson, R. F.; Ramanathan, M.; Rodriguez, T. E.; Saad, A. A.; Savani, B. N.; Schiller, G. J.; Schouten, H. C.; Schriber, J. R.; Scott, E.; Seo, S.; Sharma, M.; Ganguly, S.; Stadtmauer, E. A.; Tay, J.; To, L. B.; Vesole, D. H.; Vogl, D. T.; Wagner, J. L.; Wirk, B.; Wood, W. A.; D'Souza, A. |
| Article Title: | Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation |
| Abstract: | In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control. © 2015 Macmillan Publishers Limited. |
| Keywords: | adult; cancer chemotherapy; cancer survival; controlled study; treatment outcome; aged; major clinical study; overall survival; thalidomide; cisplatin; doxorubicin; united states; antineoplastic agent; progression free survival; bortezomib; multiple myeloma; thrombocyte; etoposide; granulocyte macrophage colony stimulating factor; cyclophosphamide; dexamethasone; retrospective study; engraftment; neutrophil; stem cell mobilization; cancer control; canada; autologous hematopoietic stem cell transplantation; human; male; female; priority journal; article |
| Journal Title: | Bone Marrow Transplantation |
| Volume: | 50 |
| Issue: | 12 |
| ISSN: | 0268-3369 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2015-12-01 |
| Start Page: | 1513 |
| End Page: | 1518 |
| Language: | English |
| DOI: | 10.1038/bmt.2015.190 |
| PROVIDER: | scopus |
| PMCID: | PMC4548821 |
| PUBMED: | 26301967 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 22 February 2016 -- Source: Scopus |
